Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBT2D2)

• Drug Name: AZD8233 Drug Info
• Synonyms: ION449

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 2	[1]
Hypercholesterolaemia	5C80.0	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMBT2D2

Molecule-Related Drug Atlas

Drug(s) Targeting PCSK9 messenger RNA (PCSK9 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inclisiran	DMP3YTE	Familial hypercholesterolemia	5C80.00	Approved	[3]
MPSK3169A	DMMRYEK	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
BMS-PCSK9	DMRCMEK	Coronary artery disease	BA80	Preclinical	[5]
ALN-PCS	DMCJMOS	Hypercholesterolaemia	5C80.0	Preclinical	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PCSK9 messenger RNA (PCSK9 mRNA)	TTNIZ2B	PCSK9_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04964557) A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia. U.S.National Institutes of Health.
• [2] AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844.
• [3] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214012.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).
• [5] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [6] Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).